Claire Mazumdar: $1.6 bn firm CEO eyes Biocon future
Biocon founder Kiran Mazumdar-Shaw has named her niece, Claire Mazumdar, as her successor. Claire Mazumdar, a successful CEO of Bicara Therapeutics, brings scientific expertise and deal-making skills. She is poised to lead Biocon into its next growth phase. The company is focusing on biosimilars and advanced biologics.
When Kiran Mazumdar-Shaw began laying out a succession plan for Biocon, one name quietly moved into focus: Claire Mazumdar.
Little known outside global biotech circles until recently, Claire Mazumdar is now emerging as the chosen successor to one of India’s most influential business leaders—positioning her at the centre of the next phase of Biocon’s evolution.
Mazumdar-Shaw, 73, told Fortune India that she has identified her niece as the future leader of the company she founded over four decades ago. “I have seen my niece Claire as my successor, because I think she has proved to me that she can run a company,” she said.
Mazumdar-Shaw indicated that the transition would be gradual, saying in a post on X that she was “not planning to hang up my boots for a while” and that Claire would “gradually transition into my role in time,” signalling continuity in leadership even as succession plans take shape.
Also Read: Biocon’s Kiran Mazumdar-Shaw chooses niece Claire Mazumdar as successor: Report
Live Events
Professional background
At 37, Claire Mazumdar brings a blend of scientific depth and deal-making experience. She is the founding CEO of Bicara Therapeutics, a U.S.-based firm incubated by Biocon that focuses on novel cancer therapies. Under her leadership, the company went public on NASDAQ in 2024 and has since grown to a market capitalisation of over $1.6 billion, even as its lead therapy remains in clinical trials.
Her career spans venture capital and drug development. She previously worked at Third Rock Ventures, where she focused on company formation and strategy, and at Rheos Medicines, where she helped steer business development, including a key partnership with Roche.
Educational background
Academically, her credentials are equally formidable. She holds a degree in biological engineering from Massachusetts Institute of Technology (MIT), an MBA from Stanford Graduate School of Business, and a PhD in cancer biology from Stanford School of Medicine. Her research in tumour immunology and cancer epigenetics has been published in leading journals including Nature and Cell Stem Cell.
Also Read: Biocon in very unique position globally as a biosimilars leader: Kiran Mazumdar-Shaw
Despite her pedigree, Claire Mazumdar has largely stayed out of the public spotlight—a contrast to her aunt, who built Biocon into India’s largest biotechnology company and a global biosimilars player.
Her elevation comes at a time of significant transition within Biocon. The company has recently merged its generics and biologics businesses, streamlined its structure and reduced debt, as it looks to strengthen its position in biosimilars, which contribute about 60% of revenue. The group is also betting heavily on advanced biologics and artificial intelligence to drive future growth.
Mazumdar-Shaw has indicated that Claire will be supported by a broader ecosystem of family and professional leaders. This includes her brother Eric Mazumdar, an artificial intelligence expert at the California Institute of Technology, and her husband Thomas Roberts of Massachusetts General Hospital.
While no formal timeline has been announced for the transition, Claire Mazumdar is expected to take on a larger role at Biocon in the foreseeable future.
For now, she remains something of an enigma—highly credentialed, globally experienced, yet largely behind the scenes. But as Biocon prepares for its next chapter, that low profile may not last much longer.
